Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2017-05-04
2020-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
NCT03511664
Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe
NCT00314535
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)
NCT03454750
Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients
NCT03237026
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
NCT03585114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Developement Cohort
Development the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
No interventions assigned to this group
Validation Cohort
Validation the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with pathologically defined prostate cancer;
* Participants with life expectancy of at least 6 months based on the Investigator's clinical judgment;
* Participants having indication and planning to receiving ADT.
Exclusion Criteria
* Participants who are allergic to contrast medium;
* Participants who failed to regulate endocrine therapy with the orders requirements;
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University Second Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuanjie Niu, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Tianjin Medical University Second Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin Medical Unversity Second Hospital
Tianjin, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRPC-PN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.